NCT00573391 · REGISTRY CONDITION SEARCH

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE3
Status at capture: TERMINATED
Registry last update: 2011-08-12

This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Participant Survival With Velcade/Melphalan/Dexamethasone Treatment vs. Participant Survival With Velcade/Thalidomide/Dexamethasone Treatment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * History of histologically documented MM previously enrolled on UARK 98-026 with relapsed or progressive disease after at least one autologous transplant. * Patient has measurable disease in which to capture response, defined as: * Serum M-protein level \> 1.0 gm/dl (10.0 g/L) measured by serum protein electrophoresis or immunoglobulin electrophoresis * Urinary M-protein excretion \> 200 mg/24 hrs * Bone marrow plasmacytosis of \> 30percent by bone marrow aspirate and/or biopsy * Serum Free Light Chains (By the Freelite test) \> 10 mg/dL with an abnormal kappa/lambda ration. * 50percent increase in size of lytic and/or focal lesions or development of new lesions recognized by radiographic studies. * Performance status of 2 as per SWOG scale, unless PS of 3-4 based solely on bone pain. * Patients must have a platelet count 50,000/mm3, unless the low platelet count is due to documented (\>30 percent) extensive myeloma infiltration of the bone marrow. * Patients must have adequate renal function defined as serum creatinine \< 2.5 mg/dl. * Patients must have adequate hepatic function defined as serum transaminases and direct bilirubin \< 2 x the upper limit of normal. * Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. * Male or female adults of at least 18 years of age. * Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations * \> 5 x 106 CD34 cells/kg in storage strongly desired, but not mandated Exclusion Criteria: * Not previously enrolled on UARK 98-026. * Has received salvage therapy after coming off UARK 98-026. * Evidence of POEMS Syndrome.. * Significant neurotoxicity interfering with ADL. * Platelet count \< 50,000/mm3 * Clinically significant hepatic dysfunction as noted by bilirubin or AST \>3 times the upper normal limit or clinically significant concurrent hepatitis. * New York Hospital Association (NYHA) Class III or Class IV heart failure. * Myocardial infarction within the last 6 months. * Truly non-secretory MM (no increase in serum free-light chains) in the absence of bone marrow plasmacytosis and MRI-defined focal lesions with CT-FNA-proven MM * Uncontrolled, active infection requiring IV antibiotics. * Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias. * Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol. * Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each dose of study drug. * Breast-feeding women may not participate.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
VTD = Velcade, Thalidomide, and Dexamethasone
intervention Names
Drug: Velcade, Thalidomide, and Dexamethasone
label
VTD = Velcade, Thal, and Dex
type
EXPERIMENTAL
description
VMD = velcade, melphalan, and dexamethasone
intervention Names
Drug: Velcade, Melphalan, and Dexamethasone
label
VMD = velcade, melphalan, and dex
type
EXPERIMENTAL

interventions

arm Group Labels
VTD = Velcade, Thal, and Dex
description
Velcade - Into vein (IV) Days 1, 4, 8, 11 Yr 1: Every 28-35 days-12 cycles Yr 2: Every 8-10 weeks- 6 cycles Thalidomide - By Mouth Days 1-28 Yr 1: Every 28-35 days-12 cycles Yr 2: Every 8-10 weeks- 6 cycles
name
Velcade, Thalidomide, and Dexamethasone
type
DRUG
arm Group Labels
VMD = velcade, melphalan, and dex
description
Velcade - Into vein (IV) Days 1, 4, 8, 11 Yr 1: Every 28-35 days-12 cycles Yr 2: Every 8-10 weeks- 6 cycles
name
Velcade, Melphalan, and Dexamethasone
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 5
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
due to low accrual rates, no analyses was done to compare the new combination of Velcade/Melphalan/Dexamethasone vs. Velcade/Thalidomide/Dexamethasone
measure
Participant Survival With Velcade/Melphalan/Dexamethasone Treatment vs. Participant Survival With Velcade/Thalidomide/Dexamethasone Treatment
time Frame
24 months

Full study description

brief Summary: This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
detailed Description: A new drug (bortezomib \[VelcadeTM PS-341\]) has been shown in recent studies to be effective in subjects with advanced multiple myeloma. There is also research that shows this drug may be even more effective when used in combination with other drugs that have been used to treat myeloma for many years (melphalan, thalidomide, and dexamethasone). This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).

Source references

references

citation
Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012 Aug 23;120(8):1597-600. doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.
pmid
22674807
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-dbb7851aba928209ddfa
requested nct id
NCT00573391
primary nct id
NCT00573391
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
14f612396acecc8c1d2d886ee53369d7e01bccee24dd8b946df855ae70db9abb
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-dbb7851aba928209ddfa
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00573391
occurrences
context exact
NCT00573391
end
11
exact text
NCT00573391
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/872/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
c03f8c37e668c678c9cecdb75c38410f150614f0cf2dc3260dfd3184043defd5
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice